Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 1997

View Archived Issues

ET antagonists prepared at Roussel Uclaf

Merck & Co. describes compound active against fungi and P. carinii

New erythromycin derivatives from Abbott

Boehringer Ingelheim discloses tachykinin antagonists

Centrally active muscarinic agents from American Home Products

NOS inhibitors disclosed by Astra for stroke and other disorders

5-HT1B receptor antagonists claimed by SKB

Zolmitriptan: a new antimigraine agent with peripheral and central sites of action

Preclinical and preliminary clinical results reported for alniditan

DuPont Merck seeks to license cholesterol-lowering agent

IND approved for multiple sclerosis drug from TCAR program

Update on clinical progression of Amylin's diabetes drug

LU-135252 evaluated in models of acute renal failure and hypertension

Xytronyx receives FDA approval to market periodontal disease test

Pharmacokinetics and antihypertensive efficacy of the new AII antagonist CS-866

SR-49059: a selective vascular V1 receptor antagonist

Single efficacy trial for transdermal buspirone required by FDA

Pharmacological profile of TBC-11251, a selective, orally active ETA antagonist

Pulmicort Turbuhaler approved by FDA

Posicor approved by FDA for hypertension and angina pectoris

ICN acquires Roche products

Pharmacokinetics of two methylprednisolone prodrugs compared in asthmatics

Zatebradine not associated with antiischemic effect in angina patients

RTP Pharma receives U.S. patent for new formulation of propofol

Minocycline superior to placebo for early RA

Amylin and J&J expand product development program

Genistein prevents ischemic retinal degeneration in rats

AMBI reports positive results with oral delivery of nisin

Dose of tirapazamine for combination chemotherapy studies selected from phase I data